Speakers: Richard Conway and Kevin Winthrop
Following publication of the ORAL Surveillance trial, Richard Conway and Kevin Winthrop discuss the impact of the findings on JAK inhibitor prescribing, how regulatory recommendations compare in Europe and the USA, and whether the risks seen with tofacitinib represent a class effect (17:12).
00:00 Introduction and overview of the trial results
03:54 Impact on current prescribing decisions
05:51 VTE and cancer risk considerations
07:56 Risk–benefit considerations in individual patients
09:21 Do the ORAL Surveillance results represent a class effect?
12:03 First- and second-line treatment options
14:00 Are there differences between adalimumab and etanercept?
14:56 Lessons learned and future research priorities
About the contributors |
|